A comparison of country-level data from the VISIONARY study examining treatment outcomes with preservative-free tafluprost/timolol fixed-dose combination therapy

CONCLUSION: Subanalysis of VISIONARY study data revealed significant IOP reductions following a switch to the PF tafluprost/timolol FC from either PGA or beta-blocker topical monotherapy. Cross-country variation was likely due to baseline IOP differences. Within country, outcomes were consistent regardless of diagnosis, dosing or prior monotherapy. Treatment was generally well tolerated.PMID:35621005 | DOI:10.1080/03007995.2022.2083324

Source: Current Medical Research and Opinion - May 27, 2022 Category: Research Authors: G ábor Holló James Kirwan Fernando Lopez-Lopez Marina Zimina Claudia Fassari Francesco Oddone VISIONARY study group Source Type: research